ImmunoGen Announces Start of IMGN388 Clinical Testing
News Jul 08, 2008
ImmunoGen, Inc. has announced the start of patient dosing in a Phase I clinical trial evaluating the Company’s IMGN388 targeted anticancer compound for the treatment of solid tumors.
IMGN388 uses ImmunoGen’s Tumor-Activated Prodrug (TAP) technology with an antibody that binds to an integrin target. ImmunoGen submitted the Investigational New Drug (IND) application for IMGN388 to the US Food and Drug Administration in mid-May 2008 and gained authorization to initiate clinical testing in mid-June 2008.
“We believe IMGN388 offers significant promise for the treatment of solid tumors, as the target for this compound is found on many types of solid tumors and also on endothelial cells in the process of forming new blood vessels,” commented John Lambert, PhD, Senior Vice President and Chief Scientific Officer.
“IMGN388 can actually attack tumors in two ways – by attaching to cancerous cells that express its target and killing them directly and by disrupting the formation of the new blood vessels that every type of solid tumor needs in order to grow. Thus, the potential opportunity for IMGN388 extends beyond tumors that express its integrin target to an even broader pool of solid tumors, “ Dr. Lambert added.
IMGN388 consists of the Company’s DM4 cell-killing agent attached to an antibody that binds specifically to an integrin expressed on a wide range of solid tumors – melanomas, sarcomas and many carcinomas, including lung, bladder, renal cell and thyroid carcinomas.
The Phase I trial (Study 201) underway at South Texas Accelerated Research Therapeutics (START) in San Antonio, TX is designed to assess the tolerability and pharmacokinetics of IMGN388 in patients with solid tumors; efficacy information also will be obtained.
Increasing doses of the compound, administered every three weeks, are to be evaluated in new cohorts of patients with solid tumors until the maximum tolerated dose (MTD) is established and the dose-limiting toxicities are identified.
Once the MTD is established, enrollment will be limited to patients with tumors that are melanomas, sarcomas or those carcinomas that characteristically express the relevant integrin target.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018